We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-7.05%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.34B
AUM Growth
+$132M
Cap. Flow
+$289M
Cap. Flow %
21.59%
Top 10 Hldgs %
54.87%
Holding
79
New
21
Increased
28
Reduced
5
Closed
19

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$72.2M
2
EXAS
Exact Sciences
EXAS
+$45.4M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$44M
4
JANX icon
Janux Therapeutics
JANX
+$34M
5
ACLX
Arcellx
ACLX
+$31.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$97.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.3M
3
AZN icon
AstraZeneca
AZN
+$27.1M
4
NARI
Inari Medical, Inc. Common Stock
NARI
+$19.9M
5
ARGX icon
argenx
ARGX
+$19.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAWN
26
DELISTED
Day One Biopharmaceuticals
DAWN
$17.2M 1.28%
+1,250,000
New +$18.3M
NARI
27
DELISTED
Inari Medical, Inc. Common Stock
NARI
$16.9M 1.26%
350,000
-450,000
-56% -$19.9M
DNTH icon
28
Dianthus Therapeutics
DNTH
$5.8B
$15.5M 1.16%
600,000
+145,000
+32% +$3.49M
SLDB icon
29
Solid Biosciences
SLDB
$790M
$15.1M 1.13%
2,665,000
+1,630,000
+157% +$14.6M
LXEO icon
30
Lexeo Therapeutics
LXEO
$330M
$13.5M 1%
840,000
+665,000
+380% +$9.66M
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$12.9M 0.96%
335,000
+110,000
+49% +$4.98M
IMNM icon
32
Immunome
IMNM
$2.61B
$12.1M 0.9%
+1,000,000
New +$15.6M
DNLI icon
33
Denali Therapeutics
DNLI
$3.67B
$11.6M 0.87%
+500,000
New +$9.6M
NRIX icon
34
Nurix Therapeutics
NRIX
$2.41B
$10.4M 0.78%
+500,000
New +$7.79M
BDTX icon
35
Black Diamond Therapeutics
BDTX
$99.7M
$9.79M 0.73%
+2,100,000
New +$11.3M
BNTX icon
36
BioNTech
BNTX
$23.3B
$8.04M 0.6%
+100,000
New +$9.14M
INSP icon
37
Inspire Medical Systems
INSP
$1.5B
$8.03M 0.6%
+60,000
New +$11.4M
PCRX icon
38
Pacira BioSciences
PCRX
$1.06B
$8.01M 0.6%
280,000
+200,000
+250% +$5.69M
DYN icon
39
Dyne Therapeutics
DYN
$4.71B
$7.94M 0.59%
+225,000
New +$6.54M
FULC icon
40
Fulcrum Therapeutics
FULC
$283M
$7.19M 0.54%
1,160,000
+465,000
+67% +$3.52M
ANRO icon
41
Alto Neuroscience
ANRO
$1.06B
$6.63M 0.49%
620,000
+370,000
+148% +$4.82M
FATE icon
42
Fate Therapeutics
FATE
$291M
$6.56M 0.49%
2,000,000
+1,200,000
+150% +$5.25M
ALLO icon
43
Allogene Therapeutics
ALLO
$635M
$5.13M 0.38%
2,200,000
+850,000
+63% +$2.51M
PASG icon
44
Passage Bio
PASG
$14.4M
$4.81M 0.36%
302,600
+77,600
+34% +$1.9M
VYGR icon
45
Voyager Therapeutics
VYGR
$181M
$4.75M 0.35%
600,000
– –
LKFT
46
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.75B
$4.46M 0.33%
180,000
+50,000
+38% +$1.42M
ZYME icon
47
Zymeworks
ZYME
$1.6B
$3.74M 0.28%
+440,000
New +$3.92M
RLMD icon
48
Relmada Therapeutics
RLMD
$556M
$3.6M 0.27%
1,200,000
– –
MGNX icon
49
MacroGenics
MGNX
$243M
$3.4M 0.25%
800,000
+75,000
+10% +$730K
GLUE icon
50
Monte Rosa Therapeutics
GLUE
$1.3B
$3.33M 0.25%
+890,000
New +$4.54M
1
2
3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Vestal Point Capital held 79 positions worth $1.34B, up 11% from $1.21B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Vestal Point Capital deployed $289M of net new capital in Q2 2024, opening 21 new positions and adding to 28 existing holdings. Its largest new stake was Janux Therapeutics: 725,000 shares worth $30.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Inari Medical, Inc. Common Stock, an estimated $19.9M trimmed.

  • Vestal Point Capital's largest Q2 2024 buy was Janux Therapeutics: 725,000 shares worth $30.4M.
  • Vestal Point Capital added most to Ultragenyx Pharmaceutical in Q2 2024, an estimated $72.2M increase.
  • Vestal Point Capital's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $19.9M.
  • Vestal Point Capital fully exited Neurocrine Biosciences in Q2 2024, selling an estimated $97.9M.
  • Vestal Point Capital's ten largest holdings make up 55% of its $1.34B portfolio in Q2 2024.
  • Vestal Point Capital opened 21 new positions and closed 19 in Q2 2024.
  • Vestal Point Capital's portfolio value rose 11% quarter-over-quarter to $1.34B.

Based on Vestal Point Capital's 13F filing for Q2 2024, filed 14 Aug 2024.